| abstract |
This invention provides new formulations for N- [4- (5H -pyrrolo [2,1-c] [1,4] benzodiazepin-10 (11H) ilcarbonyl) -3-chlorophenyl] -5-fluoro-2-methyl-benzamide , or a pharmaceutically acceptable salt thereof, and processes for making them, the formulations comprise from about 1% to about 20% of active ingredient, from about 1% to about 18% of a surfactant component, from about 50% to about 80 % of a component of one or more polyethylene glycols, from about 1% to about 20% of a component of one plus esters of sucrose and / or polyvinylpyrrolidone fatty acids and. optionally, one or more pharmaceutically acceptable preservatives or antioxidants. |